Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Merck Announces Data from Ph III Study of Investigational HIV Therapy Doravirine
Merck Announces Data from Ph III Study of Investigational HIV Therapy Doravirine
Merck Announces Data from Ph III Study of Investigational HIV Therapy Doravirine
Submitted by
admin
on July 24, 2018 - 10:11am
Source:
CP Wire
News Tags:
Merck
Doravirine
HIV
Headline:
Merck Announces Data from Ph III Study of Investigational HIV Therapy Doravirine
snippet:
At Week 96, 73.1 percent of the treatment group achieved viral suppression
Previously reported - at week 48 DOR met its primary efficacy endpoint of non-inferiority compared to DRV+r
PDUFA action date set for October 23, 2018
Do Not Allow Advertisers to Use My Personal information
